StockNoteStockNote
Imexpharm Pharmaceutical Joint Stock Company (IMP) was established in 1983, with the predecessor of Dong Thap Pharmaceutical Union Enterprise. In 2001, the Company transformed and operated in the form of a joint stock company. The company operates in the field of production and business, import and export of pharmaceutical products, medical instruments, industry raw materials. The company has 2 main production plants located in the headquarter area of Dong Thap province meeting GMP - ASEAN standards, a warehouse system meeting GSP - ASEAN standards and a laboratory meeting GLP - ASEAN standards. The IMP is granted a European visa for Cephalexin 500mg and a WHO-GMP certificate for the Health Protection Food factory. The product is produced in groups of antipyretic analgesics, antibiotics, vitamins, functional foods. In terms of market network, the Company currently has 18 branches in charge of sales nationwide. The company also cooperates with other pharmaceutical companies to become an exclusive distribution agent. IMP was officially listed on hose from December 4, 2006.
IMP currently has a market capitalization of roughly VND 5.421 billion, placing it in the mid-cap group on the Vietnamese stock market. Its current P/E of 14,8x is 24% below its own 8-year average (19,3x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 2,2x, 10% below its multi-year average of 2,5x. Return on equity (ROE) is at 15,8%. Its debt-to-equity ratio of 0,1x is low, reflecting a conservative capital structure. In 2025, revenue grew 11% year-on-year while after-tax profit grew 9%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.